Genomics and proteomics in renal cell carcinoma: Diagnosis, prognosis, and treatment selection

被引：4
|
作者：
Jones J. [1 ]
Pantuck A.J. [1 ]
机构：
[1] Department of Urology, David Geffen School of Medicine at UCLA, 66-118 Center for Health Sciences, Los Angeles
来源：
Current Urology Reports | 2008年 / 9卷 / 1期
关键词：
Renal Cell Carcinoma; Sorafenib; Sunitinib; Temsirolimus; Clear Cell Renal Cell Carcinoma;
D O I：
10.1007/s11934-008-0004-5
中图分类号：
学科分类号：
摘要：
The term renal cell carcinoma (RCC) once referred to a single entity but now encompasses a spectrum of diverse epithelial tumors with a common derivation from the renal tubular epithelium. The variable course of RCC remains problematic for patient management, despite advances in diagnosis and improved understanding of prognostic factors. However, powerful, high-throughput technologies that now analyze the entire genome and proteome promise to elucidate the heterogeneity of this disease and eventually enable a patient-tailored, individualized medicine. This review considers the clinical relevance and general significance of gene expression and protein-profiling studies. Copyright © 2008 by Current Medicine Group LLC.
引用
收藏
页码：9 / 14
页数：5
相关论文
共 50 条
  • [41] Treatment of elderly patients with metastatic renal cell carcinoma
    Zanardi, Elisa
    Grassi, Paolo
    Cavo, Alessia
    Verzoni, Elena
    Maggi, Claudia
    De Braud, Filippo
    Boccardo, Francesco
    Procopio, Giuseppe
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (03) : 323 - 334
  • [42] Interdisciplinary Recommendations for the Treatment of Metastatic Renal Cell Carcinoma
    Miller, K.
    Bergmann, L.
    Gschwend, J.
    Keilholz, U.
    Kuczyks, M.
    Wirth, M.
    AKTUELLE UROLOGIE, 2013, 44 (01) : 45 - 49
  • [43] Renal cell carcinoma diagnosis and prognosis within the context of the WHO classification 2016
    Zimpfer, A.
    Glass, A.
    Zettl, H.
    Maruschke, M.
    Hakenberg, O. W.
    Erbersdobler, A.
    UROLOGE, 2019, 58 (09): : 1057 - 1065
  • [44] Patient selection and risk factors in the changing treatment landscape of metastatic renal cell carcinoma
    Abdou, Ehab
    Pedapenki, Ravi M.
    Abouagour, Mohamed
    Zar, Abdul R.
    Dawoud, Emad
    Elshourbagy, Dalia
    Al-Shamsi, Humaid O.
    Grande, Enrique
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (10) : 831 - 840
  • [45] A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma
    Ismail, Salima
    Meskawi, Malek
    Hansen, Jens
    Bianchi, Marco
    Tian, Zhe
    Latour, Mathieu
    Graefen, Markus
    Montorsi, Francesco
    Quoc-Dien Trinh
    Perrotte, Paul
    Karakiewicz, Pierre I.
    Sun, Maxine
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2014, 90 (01) : 49 - 57
  • [46] Targeted therapies for renal cell carcinoma
    Villanueva, Mary Lee H.
    Hauke, Ralph
    TARGETED ONCOLOGY, 2007, 2 (01) : 7 - 16
  • [47] Novel drugs for renal cell carcinoma
    Vakkalanka, Bhanu K.
    Bukowski, Ronald M.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (10) : 1501 - 1516
  • [48] Targeted therapies for renal cell carcinoma
    Mary Lee H. Villanueva
    Ralph Hauke
    Targeted Oncology, 2007, 2 : 7 - 16
  • [49] Sunitinib for metastatic renal cell carcinoma
    Mukherji, Deborah
    Larkin, James
    Pickering, Lisa
    FUTURE ONCOLOGY, 2010, 6 (09) : 1377 - 1385
  • [50] CURRENT STATUS OF DIAGNOSIS AND SURGICAL TREATMENT OF RENAL CELL CARCINOMA
    Tobohov, A. V.
    Vinokurov, R. R.
    Maksimov, A. V.
    Nikolaev, V. N.
    YAKUT MEDICAL JOURNAL, 2016, (04): : 66 - 70
12345